Today, we have got Supriya Lifescience IPO Review of the company Supriya Lifescience. The company has officially announced to Issue its IPO share to the public in the share market on December 16 and will close on December 20. If you haven’t any idea about company financial structure and performance. So, we are going to provide all the necessary detail about company lot size, price, and financial reports. The company main motive is to raise around ₹700 crores through IPO that comprises fresh issue of ₹200 crores and offer for sale up to ₹500 crores with the face value of ₹2 each.
The retail investor gets a 10% quota while QIB is 75% and HNI is 15%. If you want to know company strength and their IPO detail. Then you need to stay with us till the end. In this post, you will get Supriya Lifescience IPO Dates, Prices, Listing, Allotment Status, Subscription, Grey Market Premium GMP, Review, & Details.
Supriya Lifescience IPO Review & Details
Let’s talk about the company’s background and its strength. Supriya Lifescience is a private corporation and manufacturer of Active pharmaceutical ingredients (APIs). They are one of the leading exporters of Chlorpheniramine Maleate and Ketamine Hydrochloride in India.
There are 39 APIs under suitable product range that focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin anti-asthmatic, and anti-allergic. They are exporting their products to 78 countries and over 2000 customers and over 280 distributors channel.
These are the following client’s list that deals with the company like Syntec Do Brasil LTDA, American International Chemical Inc. AT Planejamento E Desenvolvimento De Negocios LTDA, Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd, and Mankind Pharma Ltd. Check out Supriya Lifescience IPO details of the company.
Also Read: – HP Adhesives IPO: Date, Price, GMP, Allotment Status, Listing, Review, Subscription, Issue Price, & All Details
Supriya Lifescience IPO Date, Price Band, & GMP
| IPO Opening Date | Dec 16, 2021 |
| IPO Closing Date | Dec 20, 2021 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹2 per equity share |
| IPO Price | ₹265 to ₹274 per equity share |
| Market Lot | 54 Shares |
| Min Order Quantity | 54 Shares |
| Listing At | BSE, NSE |
| Issue Size | [.] Eq Shares of ₹2 (aggregating up to ₹700.00 Cr) |
| Fresh Issue | [.] Eq Shares of ₹2 (aggregating up to ₹200.00 Cr) |
| Offer for Sale | [.] Eq Shares of ₹2 (aggregating up to ₹500.00 Cr) |
| QIB Shares Offered | No less than 75% of the Offer |
| Retail Shares Offered | No more than 10% of the Offer |
| NII (HNI) Shares Offered | No more than 15% of the Offer |
Supriya Lifescience Market IPO Lot Size
The Supriya Lifescience IPO Market Lot Size is 54 shares. A retail-individual investor can apply for up to 13 lots (702 shares or ₹192,348).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 54 | ₹14,796 |
| Maximum | 13 | 702 | ₹192,348 |
Also Read: – Data Patterns IPO: Date, Price, GMP, Listing, Allotment, Issue Date, & All Details
Supriya Lifescience IPO Date, Time Table, Allotment & Listing
The Supriya Lifescience IPO Open Sate is Dec 16, 2021, and the close date is Dec 20, 2021. The issue may list on Dec 28, 2021.
| IPO Open Date | Dec 16, 2021 |
| IPO Close Date | Dec 20, 2021 |
| Basis of Allotment Date | Dec 23, 2021 |
| Initiation of Refunds | Dec 24, 2021 |
| The credit of Shares to Demat Account | Dec 27, 2021 |
| IPO Listing Date | Dec 28, 2021 |
Supriya Lifescience Financial Reports
| ₹ in crores | |||
| Income | Expense | Profit After Tax | |
| 2019 | ₹286 | ₹213 | ₹39.42 |
| 2020 | ₹323 | ₹213 | ₹73.37 |
| 2021 | ₹396 | ₹218 | ₹123.8 |
As per the company data, we have come to the conclusion that the major strength of the company is its exporting network which has spread to more than 86 countries. Also, there is a suitable price for the investor. It means it is beneficial to invest for short-term as well as long-term investors. We hope that we have provided you with enough Supriya Lifescience IPO details. We will get you more IPO reviews of companies. For more latest updates keep following us on All Social Updates.